Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:41 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 1,690 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Men Clear all
Terminated Phase 1 Interventional

A Study of FT-7051 in Men With MCRPC

NCT04575766
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
FT-7051
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Scottsdale, Arizona • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Nov 3, 2026, 1:41 AM EST
Recruiting Phase 2 Interventional

Zanzalintinib in Men With Aggressive Variant Prostate Cancer

NCT07218666
View directory record Official record
Conditions
Aggressive Variant Prostate Carcinoma
Interventions
Zanzalintinib
Drug
Lead sponsor
Deepak Kilari
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 3, 2026, 1:41 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men

NCT02816879
View directory record Official record
Conditions
Anal Carcinoma, HIV Infection, Human Papillomavirus Infection
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2028
U.S. locations
3
States / cities
Los Angeles, California • Palm Springs, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 3, 2026, 1:41 AM EST
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)

NCT03359473
View directory record Official record
Conditions
Cachexia
Interventions
GSK2881078, Matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Torrance, California • Jacksonville, Florida • High Point, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Nov 3, 2026, 1:41 AM EST
Recruiting Phase 2 Interventional

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

NCT05915442
View directory record Official record
Conditions
Oligometastatic Prostate Cancer
Interventions
Quemliclustat, Etrumadenant, Zimberelimab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Catherine Spina
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Nov 3, 2026, 1:41 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Decision Making in Men With Early Stage Prostate Cancer Patients and Partners/Close Allies

NCT01877070
View directory record Official record
Conditions
Low Risk Prostate Cancer
Interventions
assessments
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
3
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 3, 2026, 1:41 AM EST
Completed Phase 2 Interventional

Arsenic Trioxide in Treating Men With Germ Cell Cancer

NCT00036842
View directory record Official record
Conditions
Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Interventions
arsenic trioxide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
16 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
94
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Nov 3, 2026, 1:41 AM EST
Completed Phase 2 Interventional Results available

To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone

NCT00706719
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
25 mg Androxal, Testim 1%
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
21 Years to 60 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
New York, New York • Purchase, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Nov 3, 2026, 1:41 AM EST
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

NCT05713799
View directory record Official record
Conditions
Insulin Resistance, Obesity
Interventions
Alpha-lipoic acid, Mirabegron, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 3, 2026, 1:41 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

LYNX: A Novel Mobile App to Support Linkage to HIV/STI Testing PrEP for Young Men Who Have Sex With Men

NCT03177512
View directory record Official record
Conditions
HIV, Sexually Transmitted Diseases, Risk Reduction, Pre-Exposure Prophylaxis
Interventions
LYNX Mobile App
Behavioral
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
15 Years to 24 Years · Male only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Tampa, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Nov 3, 2026, 1:41 AM EST
Withdrawn Phase 2 Interventional

Testosterone for Fatigue in Men With MS

NCT03000127
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
AndroGel 1 % Topical Gel, Placebos
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Nov 3, 2026, 1:41 AM EST
Completed Phase 3 Interventional Results available

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

NCT00925600
View directory record Official record
Conditions
Cancer, Cataract, Low Bone Mineral Density, Osteopenia, Osteoporosis, Prostate Cancer
Interventions
Denosumab, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
30 Years to 120 Years · Male only
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
52
States / cities
Anaheim, California • Laguna Hills, California • Murrieta, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Nov 3, 2026, 1:41 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men

NCT02716675
View directory record Official record
Conditions
HIV Infections
Interventions
VRC01, Placebo for VRC01
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
2,699 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Nov 3, 2026, 1:41 AM EST
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate

NCT01327495
View directory record Official record
Conditions
Healthy
Interventions
placebo acyline, placebo gel, Testosterone 1% gel 1.25 g, Testosterone 1% gel 2.5 g, Testosterone 1% gel 5.0 g, testosterone 1% gel 10 g, testosterone 1% gel 15 g, Acyline
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Nov 3, 2026, 1:41 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

MI-based PrEP Intervention

NCT03313765
View directory record Official record
Conditions
PrEP Uptake
Interventions
Motivational interviewing (MI), Standard-of-care
Behavioral · Other
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Nov 3, 2026, 1:41 AM EST
Completed Phase 2 Interventional Results available

Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer

NCT01325311
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
Cholecalciferol, Genistein, Laboratory Biomarker Analysis, Pharmacological Study, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
11
States / cities
Birmingham, Alabama • Baltimore, Maryland • Burlington, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Nov 3, 2026, 1:41 AM EST
Completed Phase 2 Interventional Results available

The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)

NCT01386606
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal (enclomiphene citrate), Testosterone
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Nov 3, 2026, 1:41 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men

NCT06542536
View directory record Official record
Conditions
Obesity
Interventions
Monlunabant, Placebo (monlunabant)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Nov 3, 2026, 1:41 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

NCT01403116
View directory record Official record
Conditions
Male Hypogonadism
Interventions
Oral testosterone undecanoate, topical testosterone gel
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
25
States / cities
Birmingham, Alabama • Calera, Alabama • Huntsville, Alabama + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Nov 3, 2026, 1:41 AM EST
Completed Phase 1Phase 2 Interventional Results available

Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.

NCT02732119
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Everolimus, Exemestane
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
25
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Nov 3, 2026, 1:41 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception

NCT03452111
View directory record Official record
Conditions
Healthy, Men, Male Contraception
Interventions
Nestorone + Testosterone Combination Gel
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 50 Years
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
9
States / cities
Sacramento, California • Torrance, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Nov 3, 2026, 1:41 AM EST
Completed Not applicable Interventional

Study of Complementary Therapies in Men Receiving Radiation Therapy for Prostate Cancer: A Feasibility Trial

NCT00207259
View directory record Official record
Conditions
Prostate Cancer
Interventions
Reiki & Relaxation Response Therapy with Cognitive Restructuring
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Nov 3, 2026, 1:41 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Effects of Season on Melatonin Secretion in Healthy Men and Women and Patients With Seasonal Affective Disorder

NCT00001485
View directory record Official record
Conditions
Seasonal Affective Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 3, 2026, 1:41 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride

NCT00400335
View directory record Official record
Conditions
Hypogonadism, Hypogonadism, Male
Interventions
Nanomilled testosterone, commercially available dutasteride, Nanomilled dutasteride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Nov 3, 2026, 1:41 AM EST